IMM PE to buy Kolmar Korea’s pharma business The deal would mark the Korean PE firm’s first bet on the healthcare sector in four years
Translated by Ryu Ho-joung 공개 2020-02-25 11:37:45
이 기사는 2020년 02월 25일 08:00 thebell 에 표출된 기사입니다.
South Korea’s IMM PE is set to acquire Kolmar Korea’s pharmaceutical business, which provides contract manufacturing services to the biopharma industry, from Kolmar Korea Holdings, in the firm’s first buyout deal in the industry.Kolmar Korea Holdings has agreed to sell Kolmar Korea’s pharmaceutical unit and its entire stake in Kolmarpharma to IMM PE for 750 billion won, sources close to the matter said on February 20. The PE firm is expected to go through due diligence, before signing a share purchase agreement as early as April.
Starting with its 30 billion won investment in Celltrion Pharm in 2010, IMM PE has continued to bet on the healthcare industry, making four investments worth about 210 billion won in cumulative value during the last ten years. Most of the investments were in the form of minority stakes and mezzanine debt.
In 2012, IMM PE purchased an about 36 percent stake in Handok Pharmaceuticals from Sanofi for 74 billion won when the French drugmaker liquidated its position in the South Korean mid-sized pharmaceutical company. Six years later, IMM PE completely offloaded its holdings in the company, recording an internal rate of return of 27 percent.
The Seoul-based firm also bought 33 percent of Alvogen Korea, best known for its oral contraceptive tablet, for 60 billion won in 2012. It completed an exit from the company two years later, selling its stake for 70 billion won.
In its most recent bet on the healthcare space, IMM PE invested in South Korean biotech company iNtRON Biotechnology in 2016, purchasing 420,000 shares of the company's convertible preferred stock for 27 billion won, through its flagship fund IMM RoseGold III.
IMM PE is said to be have targeted Kolmar Korea’s pharmaceutical business assets because of the business model, in which Kolmar Korea offers contract manufacturing services to local pharmaceutical companies, including Hanmi Pharm, CJ Healthcare and Dongwha Pharm.
Such a business model is considered relatively less risky, as it does not involves activities like R&D and clinical trials. This is one of the reasons IMM PE has taken a more aggressive approach this time, seeking to acquire a controlling stake in the business.
The firm is currently working on raising capital for its fourth fund, IMM RoseGold IV, with the target fund size of more than two trillion won. The acquisition costs are expected to be financed partly through the fund, with the remaining amount likely to be funded through its co-investment fund and financing facilities provided by prospective financiers.
(By reporter Rho Ar-rum)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- [노바렉스를 움직이는 사람들]권수혜 전략기획총괄, 노바렉스 미래 그리는 지휘자
- [K-배터리 밸류업 리포트]제이오, 도전재 넘어 다각화 시동
- [이스트소프트는 지금]'알약 IPO' 특명받은 정진일 대표, 문제는 '기업가치'
- 지닥, 위믹스 많은데 '박관호 위메이드 대표 몫 못 줘'
- [탈엔비디아를 꿈꾸는 기업들]'AI 반도체 양산 임박' 모빌린트, 시험대 오른다
- [Company Watch]'애플과 멀어진' LX세미콘, DDI 대안 시급
- 외화 조달 나선 카카오, 글로벌 AI 진출 신호탄 쐈다
- [VC 투자기업]'애드테크' 버즈빌, 영업권 손상차손 93억 발생 '왜'
- [VC 투자기업]모비두, 이커머스와 매출 '윈윈' 핵심은 소스애드
- [VC 투자기업]‘전자문서 서비스’ 자버, 30억 시리즈A 나선다